GlassScriptPhysician profile
Steve K Yu
NPI 1710929724
$1,925.81
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $441 · 2021: $121 · 2022: $634 · 2023: $230 · 2024: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $432.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $660.18 | 2022-2023 | Acessa Provu System |
| Dexcom, INC. | $134.89 | 2023 | Dexcom G7 Gss (161) |
| Mimedx Group, INC. | $132.25 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2020 | |
| Abbvie INC. | $120.81 | 2019-2021 | |
| Gilead Sciences, INC. | $120.00 | 2020 | |
| Merck Sharp & Dohme LLC | $106.85 | 2019-2024 | Gardasil 9, Gardasil |
| Mylan Pharmaceuticals INC. | $92.08 | 2020-2022 | |
| Lupin INC. | $83.64 | 2019-2020 | |
| Coopersurgical, INC. | $79.98 | 2020-2024 | Endosee |
| Smith+Nephew, INC. | $78.31 | 2019 | |
| Astellas Pharma US INC | $67.33 | 2023-2024 | Veozah, Myrbetriq |
| Radius Health, INC. | $57.02 | 2019-2020 | |
| Olympus America INC. | $22.98 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.97 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $14.82 | 2021 | |
| Myovant Sciences INC. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.